3. January 2017 / by Katja Albert / 2017
Konstanz / January 3, 2017 – Sengenics, a leading molecular diagnostics and research services company in Southeastern Asia, and LifeCodexx AG, pioneer in cell-free fetal DNA testing in Europe, announced today that they have formed a partnership in the field of non-invasive prenatal testing (NIPT). Through this cooperation, pregnant women in Malaysia, Singapore, Thailand, Brunei, Vietnam, UAE and Middle East will have access to LifeCodexx’ proprietary PrenaTest® NIPT technologies.
Read more
LifeCodexx AG partners with LifeCell to launch rapid and affordable non-invasive prenatal DNA Testing (NIPT) in India
7. June 2017 / by Katja Albert / 2017
Konstanz, June 7, 2017 – LifeCodexx AG, a pioneer in non-invasive prenatal DNA testing in Europe has announced its partnership with LifeCell, India’s leading mother & baby preventive health care provider, to bring PrenaTest® qNIPT™ testing for the first time to India. The qNIPT™ technology that detects the presence of fetal trisomy 21 from […]
Read more
LifeCodexx and Charité to form research alliance following successful clinical proof-of principle for molecular genetic-based preeclampsia assay
11. April 2017 / by Katja Albert / 2017
Konstanz/Berlin, April 11, 2017 – LifeCodexx AG, a leading European NIPT provider, and the Department of Obstetrics of the Charité have formed a research alliance to intensify research and development of a novel molecular genetic-based assay for the early detection of preeclampsia, a severe disorder in pregnancy characterized by hypertension and proteinuria after the 20th week of gestation. It is the cause of approximately 16 percent of all maternal deaths in developed countries and up to 25 percent of the total perinatal mortality. Since two to eight percent of all pregnancies worldwide are affected, the incidence for preeclampsia is considerably higher than for fetal trisomy 21, for example.
Read more
LifeCodexx AG includes DiGeorge syndrome into PrenaTest® spectrum in clinical routine
18. January 2017 / by Katja Albert / 2017
Validation study and pilot projects in several European countries demonstrated highest test accuracies for the detection of the 22q11 deletion syndrome
Read more
Sengenics and LifeCodexx partner to offer NIPT in Southeast Asia
3. January 2017 / by Katja Albert / 2017
Konstanz / January 3, 2017 – Sengenics, a leading molecular diagnostics and research services company in Southeastern Asia, and LifeCodexx AG, pioneer in cell-free fetal DNA testing in Europe, announced today that they have formed a partnership in the field of non-invasive prenatal testing (NIPT). Through this cooperation, pregnant women in Malaysia, Singapore, Thailand, Brunei, Vietnam, UAE and Middle East will have access to LifeCodexx’ proprietary PrenaTest® NIPT technologies.
Read more